Longevity Biomarkers & Testing: How to Measure Your Biological Age

The question patients ask me most often when they start a longevity program is: “How do I know if any of this is working?” It’s a fair and important question. Chronological age tells you nothing about how fast you’re aging. You could be 55 and have the cardiovascular system of a 40-year-old, the insulin sensitivity of a 70-year-old, and the mitochondrial function of someone in between. The goal of longevity medicine is to identify these discrepancies — the systems aging ahead of schedule — and intervene specifically. That requires measurement.

The field of biological aging measurement has advanced dramatically in the past decade. We now have epigenetic clocks that predict mortality risk more accurately than any single blood test, functional metrics that map directly to lifespan, and a biomarker panel that captures the eight hallmarks of aging in a single blood draw. This article is the testing companion to everything else in this longevity series — it tells you which tests to get, what the numbers mean, and how to prioritize intervention based on what you find.

Biological Age vs. Chronological Age: What the Science Shows

Biological age — the pace at which your cells and tissues are aging relative to the population norm — diverges from chronological age as early as the third decade of life, and the gap widens progressively with lifestyle choices. The DUKE Dunedin Study tracked 954 people born in 1972–1973 from birth to age 38, measuring 18 biomarkers of aging at multiple time points. Even by age 38, biological aging pace (measured as rate of change in a composite of organ system health markers) varied from 0.4 years per chronological year to 2.5 years per year — meaning some 38-year-olds were aging at the rate of a 50-year-old while others were physiologically more like 30-year-olds. The fastest-aging participants looked older on facial photograph rating, had lower cognitive function, and reported worse physical health — even at age 38. This was published in PNAS in 2015 and represents one of the strongest demonstrations that biological aging divergence begins in midlife or earlier.

The practical clinical implication: chronological age is a weak predictor of health outcomes in individuals. Two 60-year-olds can have vastly different biological ages based on decades of accumulated lifestyle choices. This creates both the problem (standard medicine’s age-based treatment thresholds miss biologically young or old outliers) and the opportunity (the same interventions that appear throughout this series — exercise, sleep, anti-inflammatory diet, stress management — measurably reduce biological aging rate). The 2019 paper by Morgan Levine et al. showed that adherence to seven healthy behaviors reduced PhenoAge biological age by an average of 9 years in a nationally representative US sample. You can change your biological age; you just need a measuring stick that’s sensitive enough to detect the change.

Epigenetic Clocks: The Gold Standard Biological Age Test

DNA methylation — the addition of methyl groups to cytosine bases at CpG sites throughout the genome — changes in characteristic, predictable patterns with aging. These patterns are so consistent that algorithms trained on methylation data from thousands of people can predict a person’s age from their DNA methylation profile alone. These algorithms are called epigenetic clocks.

The first-generation Horvath clock (2013) used 353 CpG sites to predict age from any tissue with remarkable accuracy (mean absolute error of 3.6 years). Second-generation clocks improved on this by incorporating phenotypic health data alongside methylation patterns. PhenoAge (Levine et al., 2018) was trained to predict “phenotypic age” — a composite of nine blood biomarkers known to predict mortality — and was shown to predict time to disease onset and mortality more accurately than Horvath’s original clock. GrimAge (Lu et al., 2019) went further, incorporating methylation-based surrogates for smoking pack-years, lipid metabolism, tissue plasminogen activator, and other mortality-associated proteins, producing the most accurate predictor of time-to-death and time-to-disease currently available.

The clinical significance of GrimAge deceleration: intervention studies show that lifestyle changes measurably reduce epigenetic age. A 2021 Aging RCT (Fitzgerald et al.) found an 8-week diet and lifestyle program (specific foods, sleep, exercise, relaxation, probiotics, phytonutrients) reduced Horvath age by 3.23 years compared to control — in just 8 weeks. A 2023 meta-analysis of exercise interventions found regular aerobic exercise reduced various epigenetic clock ages by 0.4–1.8 years per year of consistent training. These are objective, molecular-level measurements of reversed aging. Commercial epigenetic clock tests are now available through TruDiagnostic (TruAge), Elysium (Index), and others, ranging from $200–400 for a single test. Repeat testing at 6–12 month intervals allows you to see whether your intervention program is producing measurable epigenetic deceleration.

The Complete Longevity Biomarker Panel

The comprehensive longevity biomarker panel covers the eight major biological aging pathways with blood-based tests — giving a systems-level picture of which domains need attention. Here is the complete panel I use in my functional medicine practice, organized by biological system:

Metabolic and Glycemic Health

Fasting glucose (target: 70–90 mg/dL — the range associated with lowest all-cause mortality in prospective studies); HbA1c (target: 4.8–5.2% — the non-diabetic optimal range, not just “below 5.7%”); fasting insulin (target: <5 μIU/mL fasting — elevated insulin is the earliest detectable sign of insulin resistance, appearing years before glucose dysregulation); HOMA-IR calculated from fasting glucose and insulin (target: <1.0 — ideal, <1.5 acceptable); triglycerides (target: <80 mg/dL — triglycerides >100 signal impaired fat metabolism and elevated atherogenic particle production); triglyceride/HDL ratio (target: <1.0 in mg/dL units — a surrogate for insulin resistance with strong cardiovascular predictive value).

Cardiovascular and Lipid

ApoB (target: <80 mg/dL — the direct atherogenic particle count superior to LDL-C, as covered in our cardiovascular article); Lp(a) (test once — genetically determined; >50 mg/dL or 125 nmol/L warrants aggressive risk factor management); HDL-C (target: >60 mg/dL in men, >70 mg/dL in women — but functional HDL particle quality matters more than quantity); blood pressure (target: <120/75 mmHg — the SPRINT trial threshold associated with lowest cardiovascular event rates); resting heart rate (target: <60 bpm in trained individuals — each 10 bpm increase above 60 is associated with 16% higher cardiovascular mortality).

Inflammatory and Immune Aging

hsCRP (target: <0.5 mg/L — optimal; <1.0 mg/L acceptable; >3.0 mg/L high risk); homocysteine (target: <8 μmol/L); white blood cell count (WBC target: 4.0–5.5 × 10³/μL — both high and low WBC associate with elevated mortality risk; high WBC reflects chronic immune activation, a hallmark of inflammaging); GGT/gamma-glutamyl transferase (target: <20 U/L in women, <25 U/L in men — GGT is a highly sensitive marker of hepatic oxidative stress and predicts all-cause mortality better than AST or ALT in prospective studies); ferritin (target: 30–100 ng/mL for longevity — both low ferritin (iron deficiency) and high ferritin (>200 ng/mL) associate with increased all-cause mortality and accelerated biological aging via iron-catalyzed ROS generation).

Hormonal and Endocrine Aging

DHEA-S (target: upper quartile for your age-sex group — DHEA-S declines 80–90% between ages 20 and 80 and is the most consistent hormonal longevity predictor; low DHEA-S at any age predicts cardiovascular mortality, cognitive decline, and immune senescence); free testosterone (men: target age-appropriate upper tertile; women: low-normal range with symptom-guided interpretation — testosterone deficiency in both sexes predicts sarcopenia, depression, and cardiovascular risk); IGF-1 (target: 150–250 ng/mL — both low IGF-1 (muscle wasting, cognitive decline) and high IGF-1 (>300 ng/mL, associated with cancer risk) should be avoided; the longevity sweet spot is mid-range); thyroid panel including Free T3, Free T4, TSH (target: TSH 1.0–2.0 mIU/L — the range associated with optimal metabolic function; Free T3 in the upper third of normal range; even “normal” TSH above 3.0 is associated with impaired metabolic rate, cognitive function, and cardiovascular risk in prospective studies); morning cortisol (target: 10–20 μg/dL at 8 AM — elevated morning cortisol indicates HPA axis overactivation; persistently low morning cortisol (<7 μg/dL) suggests adrenal fatigue/burnout pattern).

Nutritional and Micronutrient Biomarkers

Vitamin D (25-OH; target: 50–80 ng/mL — the range associated with lowest all-cause mortality in meta-analyses; below 30 ng/mL is associated with 50–65% higher all-cause mortality risk); omega-3 index (target: >8% EPA+DHA of red cell fatty acids — the DHA/EPA content of red blood cell membranes predicts cardiovascular mortality; most Americans test at 4–5%, indicating significant deficiency); magnesium RBC (red blood cell magnesium, NOT serum — serum magnesium is tightly regulated and misses 75% of deficiency cases; target: 5.5–7.0 mg/dL on RBC assay; magnesium deficiency accelerates aging via impaired DNA repair, mitochondrial dysfunction, and HPA axis dysregulation); zinc (serum; target: 90–120 μg/dL — zinc is required for over 300 enzymatic reactions including DNA repair and immune function; deficiency is common in older adults on proton pump inhibitors or with poor diet diversity); homocysteine (target: <8 μmol/L — repeating this here in the nutritional context because the primary treatment is nutritional: methylated B vitamins).

VO2max: The Most Powerful Functional Age Metric

If I could measure only one number to predict a patient’s healthspan and lifespan, it would be VO2max — maximal oxygen consumption during graded exercise, expressed as mL of oxygen per kilogram of body weight per minute. VO2max integrates cardiac output, blood oxygen carrying capacity, and cellular oxygen extraction — providing a single number that reflects the integrated health of the cardiovascular, pulmonary, and musculoskeletal systems simultaneously. It is the closest thing to a single number summary of biological age that exists.

The landmark 2018 study from the Cleveland Clinic by Jaber et al. analyzed VO2max and mortality in 122,007 patients over a 23-year follow-up. The findings were striking: each 1-MET (3.5 mL O2/kg/min) improvement in fitness reduced all-cause mortality by 13%. Patients in the bottom 25% of fitness had mortality rates 5× higher than the top 2.5% of fitness — a hazard ratio larger than that associated with smoking, hypertension, or type 2 diabetes. There was no upper plateau: being fitter always meant lower mortality risk, with no “too fit” threshold. The authors stated that “fitness should be considered a vital sign” — and I agree completely.

VO2max targets by age and sex (approximating the 75th percentile of physically active adults): Men: age 40–49: ≥47 mL/kg/min; age 50–59: ≥43 mL/kg/min; age 60–69: ≥38 mL/kg/min; age 70+: ≥33 mL/kg/min. Women: age 40–49: ≥42 mL/kg/min; age 50–59: ≥37 mL/kg/min; age 60–69: ≥32 mL/kg/min; age 70+: ≥27 mL/kg/min. VO2max below the 25th percentile warrants priority intervention: this is the range where mortality risk is 2–3× elevated. VO2max can be tested formally in a sports medicine laboratory with metabolic cart, estimated from submaximal bicycle tests, or estimated from heart rate recovery and exercise pace data from wearables (accuracy ±10–15% with consumer devices, sufficient for tracking trends).

How to Interpret and Act on Your Longevity Biomarker Results

A full longevity panel produces 20–30 data points — which can be overwhelming without a framework for interpretation. I use a priority triage system based on the known mortality and disease risk associated with each abnormal value. The hierarchy: address the highest-mortality-risk abnormalities first, regardless of how many “interesting” findings the panel reveals.

Tier 1 — Address immediately (highest mortality impact): HbA1c above 6.5%, blood pressure above 140/90, VO2max below 25th percentile for age, ApoB above 120 mg/dL, homocysteine above 15 μmol/L. These represent the highest-population-attributable mortality risks in the aging literature. Each of these abnormalities, untreated, carries a 30–100% excess mortality risk over 10 years.

Tier 2 — Address within 90 days: hsCRP above 3.0 mg/L, fasting insulin above 10 μIU/mL, vitamin D below 30 ng/mL, omega-3 index below 4%, GrimAge epigenetic age more than 5 years above chronological age, testosterone in the bottom quartile with symptoms, DHEA-S in the bottom quartile. These carry meaningful but somewhat slower mortality-risk escalation, and most respond to lifestyle intervention within 8–12 weeks.

Tier 3 — Optimize over 6–12 months: Triglyceride/HDL ratio above 2.0, omega-3 index between 4–8%, RBC magnesium below optimal range, ferritin above 200 ng/mL, Lp(a) above 50 mg/dL (begin aggressive Tier 1 risk management in compensation), thyroid panel suboptimal with symptoms. These represent slower-moving but compounding risks that should be addressed systematically over a program timeline.

Re-test cadence: Tier 1 biomarkers every 3–4 months until targets are achieved, then every 6 months. Tier 2 biomarkers every 6 months. Epigenetic clock annually (allows enough time for meaningful change). VO2max every 3–6 months if actively training. Lp(a) once — it doesn’t change. CAC score every 3–5 years if initially low (0–100); annually or biannually not indicated except in clinical trials.

Frequently Asked Questions

Is an epigenetic clock test worth the $200–400 cost?

For patients seriously committed to a longevity program, yes — particularly the GrimAge or PhenoAge-based tests (TruDiagnostic’s TruAge Pace of Aging and Complete tests are well-validated). The clinical value is twofold: baseline measurement tells you how your biological age compares to your chronological age and provides a systems-level starting point; repeat measurement at 12 months tells you whether your protocol is producing measurable deceleration. The alternative — running an expensive longevity protocol for years without any molecular feedback — is optimizing blind. That said, the conventional biomarker panel described above (metabolic, cardiovascular, inflammatory, hormonal) costs under $200 at direct-pay labs and provides more actionable treatment targets than an epigenetic clock alone. My recommendation: get the conventional biomarker panel first, implement a 90-day protocol based on what you find, then get the epigenetic clock test at year 1 to evaluate whether the molecular-level changes are accumulating.

What is the single most important longevity biomarker?

If forced to choose one: VO2max. The Cleveland Clinic data on 122,007 patients is definitive — VO2max predicts all-cause mortality more powerfully than any blood test, more powerfully than any disease diagnosis, and with no upper plateau. More practically: VO2max is directly and powerfully modifiable. A sedentary person who begins consistent aerobic training can improve VO2max by 15–25% within 12 weeks — an improvement that translates to roughly 2–3 fewer units of mortality hazard per year. If pressed for a blood test: HbA1c or fasting insulin. Insulin resistance is the metabolic foundation of multiple aging pathways — it drives cardiovascular disease, cognitive decline, hormonal dysregulation, and chronic inflammation simultaneously. Fasting insulin in particular detects insulin resistance a decade before HbA1c rises, giving you the maximum intervention window.

Can you reduce your biological age through lifestyle changes?

Yes — this is one of the most exciting and well-supported findings in the longevity field. The 2021 Fitzgerald et al. RCT showed 3.23 years of Horvath clock reversal in just 8 weeks of comprehensive lifestyle intervention. The 2023 meta-analysis of exercise interventions showed 0.4–1.8 years of epigenetic clock reversal per year of consistent aerobic training. A 2023 case study by David Sinclair’s group tracked a single individual through multiple rounds of plasma exchange and aggressive lifestyle optimization, showing 5+ year clock age reductions. While individual studies have limitations and the field is still maturing, the convergent evidence is clear: lifestyle interventions that reduce inflammation, improve metabolic health, and increase aerobic fitness produce measurable reductions in biological aging rate at the molecular level. The interventions that do this — which are the same interventions covered throughout this longevity series — are not optional extras for people interested in health; they are the core program for anyone who wants to extend healthspan.

Do telomere length tests provide useful longevity information?

Telomere length testing (typically measured from white blood cells via qPCR or Southern blot) is available commercially but has significant limitations as a clinical tool. While short telomeres are associated with increased aging-related disease risk at the population level, the individual predictive value is low — the intra-individual variability between blood draws and the wide population range at any given age make single-point telomere testing a poor predictor of individual outcomes. The epigenetic clocks (GrimAge, PhenoAge) have substantially better mortality prediction than telomere length in head-to-head comparisons. That said, telomere testing can be useful as part of a comprehensive panel to track change over time — the trajectory (lengthening vs. shortening) has more clinical meaning than any single measurement. The most cost-effective approach: use epigenetic clocks as your primary molecular aging readout and reserve telomere testing for specific research or high-interest clinical situations.

How does foot and ankle health appear in longevity biomarkers?

Foot and ankle health manifests in longevity biomarkers through several pathways. The ankle-brachial index (ABI) — a ratio of ankle to arm blood pressure — is a direct measure of peripheral arterial disease and predicts cardiovascular mortality independently of standard risk factors; an ABI below 0.9 warrants immediate vascular evaluation and aggressive cardiovascular risk management. Hemoglobin A1c and fasting glucose are directly relevant to the diabetic foot disease pathway — the most common cause of non-traumatic lower limb amputation in the US. Inflammatory markers (hsCRP, fibrinogen) reflect the chronic low-grade inflammation that drives diabetic neuropathy progression and impairs wound healing. In my clinical practice, every patient with abnormal foot or ankle findings gets a full metabolic and cardiovascular biomarker workup — because the foot is often where systemic disease first becomes apparent. The neuropathic foot patient who hasn’t had their HbA1c, ApoB, and hsCRP measured is being managed for a symptom without addressing the disease driving it.

Sources

• Belsky DW, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci USA. 2015;112(30):E4104–E4110. PMID: 26150497
• Lu AT, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019;11(2):303–327. PMID: 30669119
• Fitzgerald KN, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention. Aging. 2021;13(7):9419–9432. PMID: 33844651
• Jaber WA, et al. Cardiorespiratory fitness and all-cause mortality. JAMA Netw Open. 2018;1(6):e183605. PMID: 30646208
• Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573–591. PMID: 29676998
• Ross R, et al. Importance of assessing cardiorespiratory fitness in clinical practice. Circulation. 2016;134(24):e653–e699. PMID: 27881567

Dive Deeper into Longevity

• Cellular Senescence & Senolytics
• Circadian Rhythm Optimization for Longevity
• Mitochondrial Health & Longevity
• Cognitive Health & Brain Longevity